All lobbying filings

DLA Piper LLP (US)

DLA Piper LLP (US) filed a Q1 report for Regenxbio Inc. on April 16, 2026, reporting $60,000 in lobbying income.

Lobbying for Regenxbio Inc. · Biopharmaceutical company

As filed: DLA PIPER LLP (US) for REGENXBIO INC.

All filings by DLA Piper LLP (US) · Everything Regenxbio Inc. has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 16, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

Maryland

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Issues related to rare disease.

Medical/Disease Research/Clinical Labs

Issues related to rare disease.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem